LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Aktien・Krystal Biotech Inc

Krystal Biotech Inc

Geschlossen

BrancheGesundheitswesen

300.29 -2.05

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

299.29

Max

310.04

Schlüsselkennzahlen
By Trading Economics
Einkommen	4.5M 56M
Verkäufe	9.3M 116M
KGV Branchendurchschnitt	39.046 49.888
EPS	1.83
Gewinnspanne	48.069
Angestellte	295
EBITDA	16M 55M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+6.98% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	3. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	581M 8.6B
Vorheriger Eröffnungskurs	302.34
Vorheriger Schlusskurs	300.29

Nachrichtenstimmung

By Acuity

50%

155 / 344 Ranking in Healthcare

Krystal Biotech Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Juni 2026, 19:20 UTC

Wichtige Markttreiber

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

5. Juni 2026, 21:27 UTC

Ergebnisse

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5. Juni 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. Juni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5. Juni 2026, 20:20 UTC

Akquisitionen, Fusionen, Übernahmen

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5. Juni 2026, 20:19 UTC

Akquisitionen, Fusionen, Übernahmen

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5. Juni 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. Juni 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. Juni 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5. Juni 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5. Juni 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5. Juni 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5. Juni 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5. Juni 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5. Juni 2026, 18:33 UTC

Akquisitionen, Fusionen, Übernahmen

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5. Juni 2026, 17:50 UTC

Ergebnisse

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5. Juni 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5. Juni 2026, 16:48 UTC

Akquisitionen, Fusionen, Übernahmen

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5. Juni 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. Juni 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5. Juni 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5. Juni 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5. Juni 2026, 15:44 UTC

Akquisitionen, Fusionen, Übernahmen

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5. Juni 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5. Juni 2026, 15:25 UTC

Ergebnisse

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5. Juni 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. Juni 2026, 15:16 UTC

Market Talk

Zcash Tumbles After Exploit Found -- Market Talk

5. Juni 2026, 15:09 UTC

Market Talk

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

5. Juni 2026, 15:07 UTC

Market Talk

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

5. Juni 2026, 15:05 UTC

Market Talk

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Peer-Vergleich

Kursveränderung

Krystal Biotech Inc Prognose

Kursziel

By TipRanks

6.98% Vorteil

12-Monats-Prognose

Durchschnitt 322 USD 6.98%

Hoch 378 USD

Tief 284 USD

Basierend auf 10 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Krystal Biotech Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

10 ratings

Buy

Halten

Sell

Basierend auf 10 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Krystal Biotech Inc – Dist abgegeben haben.

Stimmung

By Acuity

155 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.